At Britannia Pharmaceuticals Ltd., our primary focus is the development of specialty neurology medicines. While we do not conduct in-house discovery, we actively seek innovative technologies to leverage our expertise and invest in next-generation therapies.
Additionally, we are eager to collaborate with healthcare professionals and organisations in data generation to enhance understanding of how our current treatments positively impact the lives of individuals living with Parkinson’s disease.
Our Current Areas of Research Interest based on our strategic priorities are:
Disease State: Parkinson’s Disease
• Timing for Device-Aided Therapies (DAT): Identifying the most appropriate time to initiate DATs.
• Patient Selection and Sequencing of DATs: Ensuring the right therapy is chosen for the right patient.
• Patient Sub-Typing: Identifying specific sub-types of patients who may benefit from particular DATs.
• AI Integration: Exploring how artificial intelligence can enhance the experience of patients with Advanced Parkinson’s Disease (APD).
Compound: Levodopa, Entacapone, Carbidopa, Intestinal Gel (LECIG)
• The impact of LECIG treatment on Non-Motor Symptoms
• The clinical impact of continuous COMT inhibition
• Understanding the use of LECIG in combination with, or after failure, with other DATs
• Characterising APD medication management to achieve monotherapy with LECIG
• Further understanding the characteristics of patients likely to derive benefit from LECIG
• LECIG efficacy and safety profile in subpopulations of APD patients
• Evaluation of the efficacy of LECIG using technology such as innovative imaging techniques or wearable technologies
• The impact of continuous 24-hour LECIG therapy on motor and non-motor symptoms of PD, short, medium and long-term effects.
• In patients previously treated with subcutaneous foslevodopa/foscarbidopa or levodopa/carbidopa intestinal gel (LCIG), characterising the impact of LECIG on:
– Motor symptoms e.g. morning akinesias and dystonia, fluctuations (reduction of “off” and quality of “on”), dyskinesias, freezing, motion.
– Non-motor symptoms
– Patient and caregiver satisfaction and experiences
– Quality of Life
– Healthcare resource use
• Polyneuropathy research: Levels of homocysteine (HCY) and vitamins B12, B6, and B1 in people treated with LECIG.
Compound: Apomorphine
• Evaluating apomorphine efficacy and tolerability in sub-populations of APD patients
• Understanding the use of apomorphine in combination with or after failure with other therapies
• Further understanding the characteristics of patients likely to derive benefit from apomorphine
• Exploring the influence of genetic factors on individual responses to apomorphine therapy, including genetic markers associated with treatment efficacy and adverse effects
• Cost-effectiveness of apomorphine treatment vs. other DATs
• Comparisons of efficacy and safety profile of Parkinson’s disease subcutaneous therapies
• Benefits of using apomorphine in other indications
